Active pharmaceutical ingredient for SGLT2 inhibitors in formulations addressing cardiovascular risks in type 2 diabetes. Suppliers provide to pharmaceutical manufacturers for tablet production, distributed to hospitals and clinics serving cardiologists and endocrinologists.